Targeted Oncology - Immunotherapy, Biomarkers, and Cancer …
WEBElacestrant-Abemaciclib Combo Shows Promise for Breast Cancer. By Jax DiEugenio. September 19th 2024. The ELECTRA trial found that the combination of elacestrant and abemaciclib was well-tolerated and showed promising clinical activity in patients with ER-positive, HER2-negative metastatic breast cancer who had previously received endocrine ...
Recent Approvals Signal a Bright Future for Myelodysplastic …
WEBDec 22, 2023 · Ivosidenib . In October 2023, ivosidenib (Tibsovo) was cleared by the FDA for the treatment of IDH1-mutated relapsed or refractory MDS, based on findings from the AG120-C-001 trial (NCT02074839).4 In the study, 18 adult patients with relapsed or refractory MDS with an IDH1 mutation received oral ivosidenib daily on a 28-day cycle. All responses in the trial were complete responses (CRs), and ...
Precision Medicine - Targeted Oncology
WEBJoel Neal, MD, PhD, and Alexander I. Spira, MD, PhD, FACP, talk about the role of EGFR, particularly exon 20 insertion, in NSCLC growth and progression, and review the mechanism of action and current safety and efficacy data from the mobocertinib trial.
The Rationale for Adjuvant Ovarian Suppression in Patients With ...
WEBApr 17, 2019 · 1 Premenopausal women are at an increased risk of developing ABC and have a worse prognosis than older women. 2 In addition to having factors that put them at high risk for aggressive breast cancer subtypes, young premenopausal women (typically aged ≤40 years) are at an increased risk for long-term toxicities (ie, ovarian failure) associated with currently available treatments. 2,3 ...
Advancing T-Cell Redirecting Agents in Prostate Cancer
WEBDec 17, 2021 · 1. Sartor A. Advancing the Frontiers of T-Cell Redirecting Agents in Prostate Cancer. Presented at: 28th Annual Prostate Cancer Foundation Scientific Retreat; October 28-November 5, 2021; virtual. 2. Baeuerle PA, Reinhardt C. Bispecific T-cell engaging antibodies for cancer therapy.
Overcoming Barriers to Genomic Testing in Community Care …
WEBNov 2, 2021 · Dozens of ASCO abstracts this year focused on some aspect of documenting—and then improving—genomic testing at the community-practice level. Some commonly perceived barriers to full testing include: testing prices and reimbursement; racial and socioeconomic disparities; tissue requirements; and. turnaround times.
Bridging the Gap Between Oncology and Cardiology ... - Targeted …
WEBSep 23, 2020 · Multiple cancer treatments, such as regimens that include anthracyclines and molecular targeted therapies, can cause cardiotoxicities. Patients who are at high risk for these dangerous adverse events (AEs) need to be identified and managed appropriately by educating everyone involved in the patient’s care and establishing collaboration between medical oncologists and cardiologists.
NALIRIFOX Regimen Extends Survival in Metastatic Pancreatic …
WEBNov 9, 2022 · NAPOLI 3 is a randomized, open-label study. Roughly 770 patients with mPDAC were enrolled and assigned to receive NALIRIFOX regimen twice in a month on days 1 and 15 of a 28-day cycle in the experimental arm or nab-paclitaxel and gemcitabine 3 times a month on days 1, 8, 15 of a 28-day cycle. 2. …
Precision Medicine Perspectives - Targeted Oncology
WEBApr 27, 2021 · August 30th 2021. This digital series raises awareness regarding the evolving spectrum of precision medicine in advanced prostate cancer through a review of the genomic testing and biomarker landscape as well as the rapidly developing treatment armamentarium, with an emphasis on the potential impact of these newer therapies.
Actionable Mutations Playing and Increasingly Important Role in …
WEBApr 26, 2021 · Both KRAS and EGFR mutations have become increasingly important targets in non–small cell lung cancer (NSCLC). This is especially remarkable as KRAS was once considered an “untargetable mutation.”. The NSCLC space has seen major progress over the past few years, and it may be difficult to keep up …